{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(1)"],"submitter":["Shirouchi Y"],"pubmed_abstract":["Patients with DLBCL achieving complete metabolic response (CMR) after initial treatment with R-CHOP generally have a favourable prognosis; however, there are no established prognostic biomarkers for relapse in these patients. Soluble interleukin-2 receptor (sIL-2R) levels at diagnosis are prognostic factors in patients with DLBCL. However, the significance of post-treatment sIL-2R levels is unclear. To determine the significance of post-treatment serum sIL-2R levels on subsequent relapse and survival, we retrospectively analysed 485 patients with newly diagnosed DLBCL who received R-CHOP treatment and achieved CMR. The cumulative incidence of relapse (CIR) was significantly higher in patients with elevated post-treatment sIL-2R levels than in those with normal sIL-2R levels (five-year CIR;"],"journal":["Scientific reports"],"pagination":["13713"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10444791"],"repository":["biostudies-literature"],"pubmed_title":["Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy."],"pmcid":["PMC10444791"],"pubmed_authors":["Nishimura N","Takeuchi K","Terauchi T","Hirano K","Shirouchi Y","Hirano M","Yoshida K","Asai H","Tamba M","Mishima Y","Ishihara Y","Teramoto Y","Maruyama D"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy.","description":"Patients with DLBCL achieving complete metabolic response (CMR) after initial treatment with R-CHOP generally have a favourable prognosis; however, there are no established prognostic biomarkers for relapse in these patients. Soluble interleukin-2 receptor (sIL-2R) levels at diagnosis are prognostic factors in patients with DLBCL. However, the significance of post-treatment sIL-2R levels is unclear. To determine the significance of post-treatment serum sIL-2R levels on subsequent relapse and survival, we retrospectively analysed 485 patients with newly diagnosed DLBCL who received R-CHOP treatment and achieved CMR. The cumulative incidence of relapse (CIR) was significantly higher in patients with elevated post-treatment sIL-2R levels than in those with normal sIL-2R levels (five-year CIR;","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2025-04-20T03:18:55.92Z","creation":"2025-04-20T03:18:55.92Z"},"accession":"S-EPMC10444791","cross_references":{"pubmed":["37608029"],"doi":["10.1038/s41598-023-40026-7"]}}